Shire reveals phosphate forgetfulness

Some 40 per cent of patients with chronic kidney disease forget to take phosphate binders, according to Shire Pharmaceuticals.

The study found that some of the main reasons behind the failure to take the medication was the complexity of the dosing regimen and patient concerns about the potential side-effects.

Commenting on the research, Rob Horne, professor of behavioural medicine at the University of London’s school of pharmacy, said: “We now need to develop more effective methods for helping patients to get the best from their medicines by facilitating informed choice and improved adherence.”

Professor Horne said that these goals could be achieved through providing information to individuals based on their own needs and making the dosing regimens “as convenient and easy to use as possible”.

Other findings contained within the study include that 21 per cent of patients took less medication than recommended and 19 per cent opted to miss doses.

Phosphate binders are used to treat hyperphosphataemia. If not managed properly, Shire states this condition can lead to higher rates of cardiovascular morbidity, as well as a range of other conditions.

Shire was formed in 1985 and in 2005 saw its revenues increase by 17 per cent when compared to the previous year.